2020 SGO实践声明：卵巢癌前线PARP抑制剂维持治疗

2020-08-07 美国妇科肿瘤学会 Gynecol Oncol . 2020 Aug 7;

2020年8月，美国妇科肿瘤学会(SGO)发布了卵巢癌前线PARP抑制剂维持治疗的实践声明。PARP抑制剂在卵巢癌的治疗中显示出一定的活性。本文主要针对卵巢癌初始维持治疗中应用PARP抑制剂的相关内容

中文标题：

英文标题：

Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement

发布机构：

美国妇科肿瘤学会

发布日期：

2020-08-07

简要介绍：

2020年8月，美国妇科肿瘤学会(SGO)发布了卵巢癌前线PARP抑制剂维持治疗的实践声明。PARP抑制剂在卵巢癌的治疗中显示出一定的活性。本文主要针对卵巢癌初始维持治疗中应用PARP抑制剂的相关内容提供循证决策。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=ef9321c00195a15f, title=2020 SGO实践声明：卵巢癌前线PARP抑制剂维持治疗 , enTitle=Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement, guiderFrom=Gynecol Oncol . 2020 Aug 7;, authorId=0, author=, summary=2020年8月，美国妇科肿瘤学会(SGO)发布了卵巢癌前线PARP抑制剂维持治疗的实践声明。PARP抑制剂在卵巢癌的治疗中显示出一定的活性。本文主要针对卵巢癌初始维持治疗中应用PARP抑制剂的相关内容, cover=https://img.medsci.cn/2020817/1597678583548_2020535.jpg, journalId=0, articlesId=null, associationId=1177, associationName=美国妇科肿瘤学会, associationIntro=The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women’s cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and collaborating with other domestic and international organizations., copyright=0, guiderPublishedTime=Fri Aug 07 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年8月，美国妇科肿瘤学会(SGO)发布了卵巢癌前线PARP抑制剂维持治疗的实践声明。PARP抑制剂在卵巢癌的治疗中显示出一定的活性。本文主要针对卵巢癌初始维持治疗中应用PARP抑制剂的相关内容提供循证决策。</p> </div> </div> </div>, tagList=[TagDto(tagId=359, tagName=卵巢癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21052, categoryName=梅斯医学-卵巢癌网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=359, guiderKeyword=卵巢癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5555, appHits=127, showAppHits=0, pcHits=697, showPcHits=5428, likes=1, shares=5, comments=4, approvalStatus=1, publishedTime=Mon Aug 17 23:41:12 CST 2020, publishedTimeString=2020-08-07, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Aug 17 23:36:28 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 17:03:48 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 SGO实践声明：卵巢癌前线PARP抑制剂维持治疗.pdf)])

2020 SGO实践声明：卵巢癌前线PARP抑制剂维持治疗.pdf

下载请点击：

评论区 (2)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1011402, encodeId=0b961011402f9, content=特别需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6425439702, createdName=ms6000001372871109, createdTime=Wed Aug 25 16:07:37 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809953, encodeId=41d180995302, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>，<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>作用仍很小，仅仅微有提高而已。需要突破性药物问世, beContent=null, objectType=guider, channel=null, level=null, likeNumber=291, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌), TopicDto(id=13761, encryptionId=e08113e613e, topicName=PARP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Aug 18 07:08:38 CST 2020, time=2020-08-18, status=1, ipAttribution=)]
2021-08-25 ms6000001372871109

特别需要

74 0
[GetPortalCommentsPageByObjectIdResponse(id=1011402, encodeId=0b961011402f9, content=特别需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6425439702, createdName=ms6000001372871109, createdTime=Wed Aug 25 16:07:37 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809953, encodeId=41d180995302, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>，<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>作用仍很小，仅仅微有提高而已。需要突破性药物问世, beContent=null, objectType=guider, channel=null, level=null, likeNumber=291, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌), TopicDto(id=13761, encryptionId=e08113e613e, topicName=PARP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Aug 18 07:08:38 CST 2020, time=2020-08-18, status=1, ipAttribution=)]
2020-08-18 lovetcm

#卵巢癌#，#PARP抑制剂#作用仍很小，仅仅微有提高而已。需要突破性药物问世

291 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

2020 SGO实践声明：卵巢癌前线PARP抑制剂维持治疗

相关指南

拓展阅读

科室

工具

服务